Pyramax is used to treat uncomplicated malaria, caused by two types of malaria parasites, Plasmodium falciparum and Plasmodium vivax. 'Uncomplicated' means the disease does not involve severe, life-threatening symptoms
Pyramax, a fixed-dose combination of pyronaridine and artesunate co-developed by MMV and Shin Poong Pharmaceutical Co. Ltd., South Korea, is the newest ACT combination to be approved by a Stringent Regulatory Authority.
Mode of administration The dose should be taken orally once a day for three days with or without food. Dosage in adults and children Pyramax tablets should be taken orally as a single daily dose for three consecutive days. A granule formulation is available for children weighing between 5 kg to under 20 kg